Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anastasios Stathis

Showing results (61-70 of 131) with videos related to

Pageof 14
Sort By:
British Journal of Haematology|December 9, 2022
In vitro anti-lymphoma activity of the first-in-class pan-NOTCH transcription inhibitor CB-103Filippo Spriano, Chiara Tarantelli, Alberto J Arribas, et al.
British Journal of Haematology|July 31, 2024
Targeting CD25+ lymphoma cells with the antibody-drug conjugate camidanlumab tesirine as a single agent or in combination with targeted agentsFilippo Spriano, Chiara Tarantelli, Luciano Cascione, et al.
British Journal of Haematology|July 2, 2013
Prognostic impact of monocyte count at presentation in mantle cell lymphomaKathrin Aprile von Hohenstaufen, Annarita Conconi, Cassio Polpo de Campos, et al.
Cancers|June 12, 2026
A Phase Ib Trial of Copanlisib in Combination with Venetoclax in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma-SAKK 66/18 TrialMaria Cristina Pirosa, Dagmar Hess, Fatime Krasniqi, et al.
Hematological Oncology|September 26, 2024
Superior prognostic accuracy of FIGO staging system in primary female genital tract lymphomas: A retrospective study (IELSG35)Maria Cristina Pirosa, Sara Steffanoni, Anna Vanazzi, et al.
Exploration of Targeted Anti-Tumor Therapy|September 1, 2022
The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like typeChiara Tarantelli, Eleonora Cannas, Hillarie Ekeh, et al.
Ejhaem|September 2, 2022
Pharmacologic screen identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphomaFilippo Spriano, Giulio Sartori, Chiara Tarantelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 8, 2018
Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid TumorsJeremy Lewin, Jean-Charles Soria, Anastasios Stathis, et al.
Leukemia & Lymphoma|June 12, 2010
Patterns of survival of follicular lymphomas at a single institution through three decadesAnnarita Conconi, Maddalena Motta, Francesco Bertoni, et al.
Blood Advances|May 17, 2021
Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitorsAfua Adjeiwaa Mensah, Filippo Spriano, Giulio Sartori, et al.
Pageof 14

Showing results (61-70 of 131) with videos related to

Sort By:
Pageof 14
British Journal of Haematology|December 9, 2022
In vitro anti-lymphoma activity of the first-in-class pan-NOTCH transcription inhibitor CB-103Filippo Spriano, Chiara Tarantelli, Alberto J Arribas, et al.
British Journal of Haematology|July 31, 2024
Targeting CD25+ lymphoma cells with the antibody-drug conjugate camidanlumab tesirine as a single agent or in combination with targeted agentsFilippo Spriano, Chiara Tarantelli, Luciano Cascione, et al.
British Journal of Haematology|July 2, 2013
Prognostic impact of monocyte count at presentation in mantle cell lymphomaKathrin Aprile von Hohenstaufen, Annarita Conconi, Cassio Polpo de Campos, et al.
Cancers|June 12, 2026
A Phase Ib Trial of Copanlisib in Combination with Venetoclax in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma-SAKK 66/18 TrialMaria Cristina Pirosa, Dagmar Hess, Fatime Krasniqi, et al.
Hematological Oncology|September 26, 2024
Superior prognostic accuracy of FIGO staging system in primary female genital tract lymphomas: A retrospective study (IELSG35)Maria Cristina Pirosa, Sara Steffanoni, Anna Vanazzi, et al.
Exploration of Targeted Anti-Tumor Therapy|September 1, 2022
The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like typeChiara Tarantelli, Eleonora Cannas, Hillarie Ekeh, et al.
Ejhaem|September 2, 2022
Pharmacologic screen identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphomaFilippo Spriano, Giulio Sartori, Chiara Tarantelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 8, 2018
Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid TumorsJeremy Lewin, Jean-Charles Soria, Anastasios Stathis, et al.
Leukemia & Lymphoma|June 12, 2010
Patterns of survival of follicular lymphomas at a single institution through three decadesAnnarita Conconi, Maddalena Motta, Francesco Bertoni, et al.
Blood Advances|May 17, 2021
Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitorsAfua Adjeiwaa Mensah, Filippo Spriano, Giulio Sartori, et al.
Pageof 14